Tomás Pascual, Maria Vidal, Juan Miguel Cejalvo, Estela Vega, Esther Sanfeliu, Guillermo Villacampa, Sergi Ganau, Ana María Julve Parreño, Esther Zamora, Ignacio Miranda, Ana Sofia Delgado, B. Bermejo, E Seguí, Fara Brasó-Maristanty, Luis de la Cruz-Merino, M. Juan, Patricia Galván, Xavier González, Samyukta Chillara, Patricia Villagrasa, Adam D. Pfefferle, Constandina E O'Connell, Juan Manuel. Ferrero-Cafiero, Mafalda Oliveira, Charles M. Perou, A. Prat
PFU/mL) plus atezolizumab (840 mg, intravenously). Among the 28 patients enrolled, 20 patients (71.4%) had HR+/HER2-negative and 8 patients (28.6%) had TNBC. At surgery, 7 patients (26.9%) achieved Residual Cancer Burden (RCB)-0/I (primary endpoint), 12 (46.2%) RCB-II and 7 (26.9%) RCB-III. Safety profile was favorable, with mostly low-grade adverse events and no serious events (secondary endpoint). Therapy induced immune modulation, including increased tumor-infiltrating lymphocytes, elevated PD-L1 expression, and enhanced immune-related gene signatures (exploratory endpoints). The trial met its pre-specified efficacy and safety endpoints. These findings support the feasibility of T-VEC plus atezolizumab as a preoperative immunotherapy approach for managing HER2-negative residual disease post-neoadjuvant chemotherapy and warrant further exploration in larger trials.